Recombinant anti- human ErbB2/HER2 Antibody (Trastuzumab) FITC Conjugated

Target: ErbB2 Trade name: Samceptin Generic name: Trastuzumab Product Origin: Recombinant in CHO cells Product Construction: Immunoglobulin G1, anti- (human p185neu receptor) (human-mouse monoclonal rhuMab HER2 g1- chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer. The drug Trastuzumab (Brand name Herceptin®, From Roche/Genentech) is a monoclonal antibody and works by targeting breast cancer cells that overexpress the HER2 protein. Overexpression (or amplification) of the HER2 protein is associated with accelerated cell division. By binding to the protein receptors on these cells, Trastuzumab interrupts the growth signal, thereby slowing the growth and spread of tumors. Approximately 20% of breast cancers overexpress the HER2 protein. Amplification of HER2 in breast cancer cells has been correlated with adverse prognostic factors such as large tumor size, high nuclear grade, and decreased expression of estrogen and progesterone hormone receptors. HER2 amplification has also been associated with reduced disease-free survival, and overall survival, for women with node-positive or node negative disease. Trastuzumab (anti-p185, rhuMab HER2), which is a humanized monoclonal antibody that binds to the HER2 protein. HER-2 is a transmembrane spanning receptor-like protein, which is structurally related to the epidermal growth factor receptor and has been shown to inhibit the proliferation of human tumor cells that overexpress HER2 both in vitro and in vivo. The developed biosimilar to Herceptin, designated as Samceptin. The biochemical characterizations and the functional assays suggest that Samceptin is highly similar in structure and activity to Herceptin. *Disclaimer: Herceptin® is a registered trademark of Genentech, Inc. Samceptin can only be used for research purposes. Not to be used as diagnostic for therapeutic purposes.